OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy?

Core Insights - OmniAb, Inc. (OABI) is anticipated to report a year-over-year increase in earnings driven by higher revenues for the quarter ending September 2025, with a consensus outlook suggesting a quarterly loss of $0.14 per share, reflecting a 12.5% improvement from the previous year [1][3] - Revenues are projected to reach $6.05 million, marking a significant increase of 45.1% compared to the same quarter last year [3] Earnings Expectations - The upcoming earnings report is scheduled for November 4, and the stock may experience upward movement if the reported figures exceed expectations, while a miss could lead to a decline [2] - The consensus EPS estimate has been revised 3.33% higher in the last 30 days, indicating a positive reassessment by analysts [4] Earnings Surprise Prediction - The Zacks Earnings ESP (Expected Surprise Prediction) model indicates that OmniAb, Inc. has a positive Earnings ESP of +15.79%, suggesting a strong likelihood of beating the consensus EPS estimate [12] - The company currently holds a Zacks Rank of 2, further supporting the expectation of an earnings beat [12] Historical Performance - In the last reported quarter, OmniAb, Inc. was expected to post a loss of $0.14 per share but actually reported a loss of -$0.15, resulting in a surprise of -7.14% [13] - Over the past four quarters, the company has only surpassed consensus EPS estimates once [14] Industry Context - Another company in the Zacks Medical - Drugs industry, Karyopharm Therapeutics (KPTI), is expected to report a loss of $3.3 per share for the same quarter, reflecting a year-over-year change of +15.4% [18] - Karyopharm's revenues are anticipated to be $42.3 million, up 9.1% from the previous year, but it has an Earnings ESP of 0%, making predictions about beating the consensus EPS estimate uncertain [19][20]